PrecisionNCT07486648
Osimertinib Plus Capivasertib in NSCLC With PIK3CA/AKT1/PTEN Alterations Following Prior 1L Osimertinib
StatusNot Yet Recruiting
PhasePhase 1/2
Primary completion (estimated)
At risk: Primary completion moved 7 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary completion pushed from Oct 15, 2028 to May 15, 2029 Show 6 more changesShow less
- Start date: May 15, 2026 to Dec 8, 2026
- Eligibility criteria expanded, about 66 words
- Primary endpoints: details revised at 1 of 4 entries
- Study completion pushed from Dec 31, 2028 to Jul 31, 2029
- Secondary endpoints: details revised at 2 of 8 entries
- Publications: details revised at 30 of 36 entries
- Minor Site contacts updated at 2 of 2 sitesv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Part A Number of Dose-limiting toxicities (DLTs)
Timeframe: 28 days post first dose of study treatment
Part A Adverse events (AEs)/serious adverse events (SAEs) (graded by CTCAE Version 5.0)
Timeframe: From the time of signature of informed consent form up to 44 months
Part A Recommended combined dose (RCD)
Timeframe: From first dose of study treatment up to 12 months
Part B Confirmed ORR assessed by the Investigator per RECIST 1.1 criteria
Timeframe: 5 months post first dose of study treatment
Secondary (8)
Part A Confirmed ORR assessed by the Investigator per RECIST 1.1 criteria
Part B Progression-free survival(PFS)
Part B Duration of response(DoR )
Part B Disease control rate(DCR)
Part B Overall survival(OS)
Show 3 moreShow less
Part B AE/SAE
Part B Adverse drug reactions(ADR)
Part B Adverse events of special interest(AESI)
Arms and interventions
Capivasertib 320/400 mg in combination with Osimertinib 80mgExperimental
Capivasertib 320/400 mg (twice daily from day 1 to 4 of a 7-day cycle ),Osimertinib 80 mg( once daily continuously),28 days per cycle
Drugs: Capivasertib in combination with Osimertinib
Sites
2 sites in 1 country